Neurocrine Biosciences
NBIX
NBIX
417 hedge funds and large institutions have $11.1B invested in Neurocrine Biosciences in 2020 Q2 according to their latest regulatory filings, with 89 funds opening new positions, 168 increasing their positions, 112 reducing their positions, and 36 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
9% more call options, than puts
Call options by funds: $71.2M | Put options by funds: $65.4M
0.79% less ownership
Funds ownership: 98.94% → 98.16% (-0.79%)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
Holders
417
Holding in Top 10
8
Calls
$71.2M
Puts
$65.4M
Top Buyers
| 1 | +$132M | |
| 2 | +$117M | |
| 3 | +$93.4M | |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$82.6M |
| 5 |
BlackRock
New York
|
+$67.3M |
Top Sellers
| 1 | -$145M | |
| 2 | -$138M | |
| 3 | -$112M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$104M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$61.4M |